Opioid combination for cancer pain by Mercadante, S
Letter to the Editor
Opioid combination for cancer pain
S Mercadante*,1
1Pain Relief & Palliative Care Unit, La Maddalena Cancer Center, Via San Lorenzo 312, Palermo 90146, Italy
British Journal of Cancer (2004) 90, 2049. doi:10.1038/sj.bjc.6601806 www.bjcancer.com
Published online 13 April 2004
& 2004 Cancer Research UK
                
Sir,
I read with interest the paper by Lauretti et al (2003) regarding
the possible advantage of combining opioids in cancer pain
management. They report in a crossover study that the morphine
consumption given as rescue doses of immediate release morphine
was lower in the oxycodone phase rather than during morphine
phase. Moreover, nausea and vomiting were less frequent in
oxycodone phase. While the idea of combining opioids is
fascinating, data reported can merely be the result of the
conversion ratio used between oxycodone and morphine, which
remains unclear, and/or of the individual response when switching
from one drug to another during crossover. This may occur in
patients treated with a certain drug and receiving another drug as
needed, for which they are less tolerant, or in other terms more
responsive. Of course, nausea and vomiting will be more
frequently observed in patients who will require more extra doses
of morphine.
On the other hand, combination of opioids can be really
effective for other reasons, other than the obvious disparity in
effecting different receptor subgroups and specificity, as reported
to explain the benefits of opioid switching, Anecdotally, multiple
opioids are often simultaneously administered for different
reasons, although it should be considered a nonsense approach.
However, recent experimental data have offered a rationale for
using different opioids in an attempt to improve the analgesia or to
limit the development of tolerance in difficult conditions such as
the need for rapid escalation. Authors report experimental studies
in animals where subantinociceptive doses of oxycodone were
given with morphine, resulting in a synergic analgesic effect, but in
their study they are administering presumably equianalgesic doses
of the two opioids (Ross et al, 2000). This observation seems to be
attributed to a significant variability among opioid drugs in
inducing rapid endocytosis of opioid receptors. This is an
independent functional property that distinguishes clinically
opioid drugs. Recently, the regulation of opioid receptors
by endocytosis has been hypothesised to have protective
functions in reducing the development of tolerance. Agonist
activity and receptor endocytosis have opposing effects on
receptor-mediated signalling, and the final result is a function of
both processes (named RAVE). Morphine, in comparison with
other opioids, has a high activity-endocytosis ratio, and has
an enhanced propensity to prolonging signals with prolonged
drug exposure. Molecular events, such as desensitisation
and endocytosis, would reduce this response. It has been
experimentally demonstrated that endocytosis-promoting agonists
may facilitate morphine-induced receptor endocytosis, reducing
the compensatory adaptive cellular changes that lead to
upregulation of the cAMP pathway (He et al, 2002). Thus,
a combination of opioids with different characteristics may
reciprocally alter their RAVEs, so reducing the potential for
the development of tolerance. In the clinical setting, the
administration of small doses of a second opioid in patients with
an unfavourable response during escalation with the prior opioid
has been found effective in a preliminary experience, not yet
published by our group. According to these observations, opioid
‘semiswitching’ could be a new therapeutic option in patients
requiring escalating doses of opioids. A better knowledge of
molecular mechanisms that modulate the opioid response may
offer alternative treatments, which should be tested in the clinical
setting. These data, supported by recent molecular investigation,
should be considered preliminary and should be confirmed in a
larger number of patients in controlled studies.
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